Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$4.18
−$0.13 · -3.02%
Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These remedies are designed to address common chronic health issues prevalent among the elderly, promoting physical well-being and longevity, in addition to offering medications for cold and flu symptoms. Beyond its own manufactured goods, UPC also functions as a distributor and vendor for a diverse range of third-party products. This extensive portfolio includes biomedical drugs, medical instruments, traditional Chinese medicine 'pieces' (raw ingredients), and various dietary supplements. Its clientele spans across the healthcare sector, encompassing other pharmaceutical companies, hospitals, clinics, and major drugstore chains. Established in 2019, the company's operations are headquartered in Ji'An, China, and it functions as a subsidiary of Sununion Holding Group Limited.
Latest quote
$4.18
−$0.13 · -3.02%
After-hours
$4.10
−$0.08 · -1.91%
Oct 8, 5:59 PM ET
Regular session · ET · Market data may be delayed.
Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These remedies are designed to address common chronic health issues prevalent among the elderly, promoting physical well-being and longevity, in addition to offering medications for cold and flu symptoms. Beyond its own manufactured goods, UPC also functions as a distributor and vendor for a diverse range of third-party products. This extensive portfolio includes biomedical drugs, medical instruments, traditional Chinese medicine 'pieces' (raw ingredients), and various dietary supplements. Its clientele spans across the healthcare sector, encompassing other pharmaceutical companies, hospitals, clinics, and major drugstore chains. Established in 2019, the company's operations are headquartered in Ji'An, China, and it functions as a subsidiary of Sununion Holding Group Limited.
Day range
Current $4.18
52-week range
Current $4.18
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
67
Undervalued
Sentiment
54
Mixed
Risk
73
High Risk
Momentum
54
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These remedies are designed to address common chronic health issues prevalent among the elderly, promoting physical well-being and longevity, in addition to offering medications for cold and flu symptoms. Beyond its own manufactured goods, UPC also functions as a distributor and vendor for a diverse range of third-party products. This extensive portfolio includes biomedical drugs, medical instruments, traditional Chinese medicine 'pieces' (raw ingredients), and various dietary supplements. Its clientele spans across the healthcare sector, encompassing other pharmaceutical companies, hospitals, clinics, and major drugstore chains. Established in 2019, the company's operations are headquartered in Ji'An, China, and it functions as a subsidiary of Sununion Holding Group Limited.
Day range
Current $4.18
52-week range
Current $4.18
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 17.86M USD | 23.02M USD | 32.31M USD | 40.14M USD | 47.98M USD |
| Cost of goods sold | 11.56M USD | 16.95M USD | 21.99M USD | 18.25M USD | 22.66M USD |
| Gross profit | 6.3M USD | 6.07M USD | 10.32M USD | 21.89M USD | 25.33M USD |
| Research and development | 671.76K USD | 3.03M USD | 4.86M USD | 7.62M USD | 5.47M USD |
| Selling, general, and administrative | 8M USD | 10.44M USD | 9M USD | 21.3M USD | 6.27M USD |
| Operating expenses | 9.22M USD | 14.09M USD | 13.84M USD | 28.91M USD | 11.74M USD |
| Interest expense | 232.04K USD | 278.17K USD | 156.79K USD | 162.4K USD | 101.6K USD |
| Depreciation and amortization | 517.43K USD | 485.73K USD | 508.79K USD | 533.95K USD | 446.88K USD |
| Operating income | −2.92M USD | −8.02M USD | −3.53M USD | −7.02M USD | 13.59M USD |
| Net income | −3.67M USD | −8.73M USD | −6.16M USD | −8.74M USD | 11.32M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Mar 24, 2025 | 1:40 | — | — |
Stock split | Nov 18, 2024 | 1:15 | — | — |
Stock split | Jul 28, 2023 | 1:6 | — | — |
Effective Mar 24, 2025
1:40
Effective Nov 18, 2024
1:15
Effective Jul 28, 2023
1:6
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
